메뉴 건너뛰기




Volumn 75, Issue , 2014, Pages S38-S41

Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides

Author keywords

anti tumor necrosis factor (TNF); drug survival; inflammatory arthritides

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

EID: 84910047010     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21192     Document Type: Review
Times cited : (37)

References (9)
  • 1
    • 34147219117 scopus 로고    scopus 로고
    • Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
    • BIOBADASER Group.
    • Carmona L, Gomez-Reino JJ, BIOBADASER Group. 2006. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8: R72.
    • (2006) Arthritis Res Ther , vol.8 , pp. R72
    • Carmona, L.1    Gomez-Reino, J.J.2
  • 3
    • 84894903634 scopus 로고    scopus 로고
    • Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival
    • et al.
    • Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, et al. 2014. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43: 447-457.
    • (2014) Semin Arthritis Rheum , vol.43 , pp. 447-457
    • Flouri, I.1    Markatseli, T.E.2    Voulgari, P.V.3    Boki, K.A.4    Papadopoulos, I.5    Settas, L.6    Zisopoulos, D.7    Skopouli, F.N.8    Iliopoulos, A.9    Bertsias, G.K.10
  • 4
    • 70350605186 scopus 로고    scopus 로고
    • Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period
    • BIOBADASER Group.
    • Gomez-Reino JJ, Carmona L, BIOBADASER Group. 2006. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8: R29.
    • (2006) Arthritis Res Ther , vol.8 , pp. R29
    • Gomez-Reino, J.J.1    Carmona, L.2
  • 5
    • 74849094402 scopus 로고    scopus 로고
    • Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
    • et al.
    • Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. 2010. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62: 22-32.
    • (2010) Arthritis Rheum , vol.62 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3    Dreyer, L.4    Hansen, A.5    Hansen, I.T.6    Kollerup, G.7    Linde, L.8    Lindegaard, H.M.9    Poulsen, U.E.10
  • 6
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • British Society for Rheumatology Biologics Register.
    • Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, British Society for Rheumatology Biologics Register. 2007. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13-20.
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • Hyrich, K.L.1    Lunt, M.2    Watson, K.D.3    Symmons, D.P.M.4    Silman, A.J.5
  • 7
    • 84861811932 scopus 로고    scopus 로고
    • Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: An appraisal of predictors
    • et al.
    • Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, et al. 2012. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39: 1179-1184.
    • (2012) J Rheumatol , vol.39 , pp. 1179-1184
    • Iannone, F.1    Gremese, E.2    Atzeni, F.3    Biasi, D.4    Botsios, C.5    Cipriani, P.6    Ferri, C.7    Foschi, V.8    Galeazzi, M.9    Gerli, R.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.